Posts

Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses – key facts and context

on

Biopharma Bites: Boehringer’s 2Q, Keytruda Expansion, and Wegovy’s Market Domination

on

The Oral GLP-1 Tracker: Novo’s Wegovy keeps gaining ground in obesity market

on

Oral GLP‑1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch

on

Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook

on

Novo Nordisk Q1: Pills, Pricing, Payments, Pressure

on

Boehringer Ingelheim and Zealand Pharma's Survodutide Matches Wegovy in Weight Loss but Trails Zepbound in Phase 3 Trial

on

Trump Administration Indefinitely Delays Medicare Weight-Loss Drug Pilot Program

on

Novo Nordisk Launches Discounted Multi-Month Subscription Program for Wegovy via Telehealth Providers

on

Eli Lilly's Orforglipron Obesity Pill Gains FDA Approval, Challenging Novo Nordisk's Wegovy

on

No Recent NICE Cardio Approval for Wegovy

on

Novo Nordisk Launches Discounted Subscription Program for Wegovy

on

Novo Nordisk's GLP-1 Pipeline Advances with Oral Innovations Amid Analyst Concerns on Oral Trends

on

Novo Nordisk's High-Dose Wegovy Receives FDA Approval Under Commissioner's Voucher Program

on

Novo Holdings Assets Shrink by a Third Due to Novo Nordisk's Falling Share Price

on

Hims Agrees to Limit Compounding, Ending Legal Dispute with Novo Nordisk

on

Hims Pharmacy Partner Plans to Reintroduce GLP-1 Pill Pulled from Market Amid Regulatory Backlash

on

Novo Nordisk Announces 50% Wegovy List Price Cut to $675 Starting January 2027

on

Friday Five: Novo Nordisk Sues Hims & Hers Over Compounded GLP-1 Drugs Amid FDA Crackdown

on

Friday Five: Novo Nordisk Sues Hims & Hers Over Compounded GLP-1 Drugs Amid FDA Crackdown

on